Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 2,950,000 shares, an increase of 13.9% from the December 15th total of 2,590,000 shares. Based on an average daily trading volume, of 335,500 shares, the days-to-cover ratio is currently 8.8 days. Currently, 15.8% of the shares of the stock are sold short.
Shares of KYTX stock opened at $3.33 on Friday. Kyverna Therapeutics has a 52-week low of $3.24 and a 52-week high of $35.06. The company's 50 day moving average is $4.32 and its 200 day moving average is $6.00.
Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. Sell-side analysts expect that Kyverna Therapeutics will post -3.29 EPS for the current year.
Large investors have recently made changes to their positions in the business. Novo Holdings A S lifted its position in Kyverna Therapeutics by 150.0% during the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company's stock valued at $13,125,000 after purchasing an additional 1,050,000 shares during the period. Deerfield Management Company L.P. Series C raised its stake in shares of Kyverna Therapeutics by 35.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company's stock valued at $14,872,000 after buying an additional 520,663 shares during the last quarter. MBB Public Markets I LLC acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at about $3,076,000. Kera Capital Partners Inc. purchased a new stake in shares of Kyverna Therapeutics in the fourth quarter worth about $1,407,000. Finally, Great Point Partners LLC grew its holdings in Kyverna Therapeutics by 232.8% during the second quarter. Great Point Partners LLC now owns 499,152 shares of the company's stock worth $3,744,000 after acquiring an additional 349,152 shares during the period. 18.08% of the stock is owned by hedge funds and other institutional investors.
Several analysts recently issued reports on KYTX shares. Rodman & Renshaw initiated coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a "buy" rating and a $16.00 target price for the company. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a "strong-buy" rating in a report on Wednesday, October 9th. HC Wainwright decreased their price target on Kyverna Therapeutics from $7.00 to $6.00 and set a "neutral" rating on the stock in a report on Wednesday, November 20th. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They issued a "buy" rating and a $13.00 price objective on the stock. Finally, Wells Fargo & Company lowered their target price on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Kyverna Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $25.71.
Check Out Our Latest Stock Report on Kyverna Therapeutics
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.